- Home
- VXRT vs FULC Comparison
VXRT vs FULC Comparison
Compare VXRT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VXRT
- FULC
- Stock Information
- Founded
- VXRT N/A
- FULC 2015
- Country
- VXRT United States
- FULC United States
- Employees
- VXRT N/A
- FULC N/A
- Industry
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- VXRT Health Care
- FULC Health Care
- Exchange
- VXRT Nasdaq
- FULC Nasdaq
- Market Cap
- VXRT 200.3M
- FULC 221.5M
- IPO Year
- VXRT N/A
- FULC 2019
- Fundamental
- Price
- VXRT $0.76
- FULC $4.00
- Analyst Decision
- VXRT Strong Buy
- FULC Hold
- Analyst Count
- VXRT 2
- FULC 10
- Target Price
- VXRT $3.00
- FULC $7.44
- AVG Volume (30 Days)
- VXRT 2.6M
- FULC 911.1K
- Earning Date
- VXRT 03-13-2025
- FULC 02-25-2025
- Dividend Yield
- VXRT N/A
- FULC N/A
- EPS Growth
- VXRT N/A
- FULC N/A
- EPS
- VXRT N/A
- FULC N/A
- Revenue
- VXRT $16,760,000.00
- FULC $80,871,000.00
- Revenue This Year
- VXRT $128.77
- FULC $2,821.96
- Revenue Next Year
- VXRT N/A
- FULC N/A
- P/E Ratio
- VXRT N/A
- FULC N/A
- Revenue Growth
- VXRT 303.27
- FULC 2987.86
- 52 Week Low
- VXRT $0.52
- FULC $2.86
- 52 Week High
- VXRT $1.54
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- VXRT 55.26
- FULC 42.82
- Support Level
- VXRT $0.70
- FULC $3.90
- Resistance Level
- VXRT $0.83
- FULC $5.17
- Average True Range (ATR)
- VXRT 0.09
- FULC 0.29
- MACD
- VXRT -0.00
- FULC -0.12
- Stochastic Oscillator
- VXRT 36.62
- FULC 7.87
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.